Plenge Robert M 4

What Happened

• Robert M. Plenge, EVP and Chief Research Officer of Bristol Myers Squibb (BMY), reported multiple award-related transactions on March 10, 2026. Several derivative awards (exercise/conversion and grants) converted into shares (M and A codes).
• Tax withholding/cashless settlements: 436, 927 and 3,172 shares were withheld/disposed to cover taxes at $60.13 per share, totaling $272,690.
• Other administration-type dispositions (J codes) totaling 124, 253 and 6,900 shares were recorded at $0 proceeds (these reflect internal/administrative transfers or adjustments, not open-market sales).

Key Details

• Transaction date: March 10, 2026. Form filed March 12, 2026 (appears timely).
• Withholding price: $60.13 per share for tax payments; total tax-withheld value = $272,690 for 4,535 shares.
• Award/derivative activity recorded: exercise/conversion entries of 1,107; 2,342; and 14,052 shares (M) and grant/award entries of 17,959 and 26,939 derivative units (A). Several matching J and M entries reflect settlement/administrative steps.
• Shares owned after the transactions: not specified in this Form 4.
• Notable footnotes: awards stem from prior market-share and performance-share unit grants (vesting dates March 10, 2022 and 2023 and long-term performance awards). Footnotes explain payout factors for market share units (performance-based scaling) and that some performance share units convert into one share on distribution.
• Transaction codes: M = option/derivative exercise or conversion; A = award/grant; F = payment of exercise price / tax withholding; J = other acquisition/disposition.

Context

• These filings reflect vesting/conversion of compensation awards and related tax withholding (a form of cashless settlement), rather than open-market purchases or discretionary sales. Such transactions are typically routine compensation events; they do not, by themselves, indicate insider sentiment about the stock price.